Background: The aim of this study was to identify factors associated with relapse in panic disorder (PD).
C ognitive-behavioral therapy (CBT), antidepressants, benzodiazepines, and other drugs are considered effective treatments for panic disorder (PD), and the response rates in short-term treatment are high.
1,2 Panic symptoms may linger more than a year in some patients, 3 but true treatment-resistant patients are few. 4, 5 Meanwhile, relapse is very common in patients with this anxiety disorder. 3, [5] [6] [7] [8] Persistence of PD as a chronic or recurrent disorder impacts well-being, self-rated health, functional impairment, and work-related problems and entails considerable economic costs to society. 6, 9 Benzodiazepines [10] [11] [12] and selective serotonin reuptake inhibitors (SSRIs) 11, 13 are 2 drug classes with proven efficacy in treating PD. In a meta-analysis of 53 studies including 7725 patients with PD who received pharmacological treatment, benzodiazepines and SSRIs showed comparable efficacy.
14 Selective serotonin reuptake inhibitors have been prescribed for PD with or without agoraphobia for over a decade and are recommended as first-line treatment for PD on the basis of their favorable safety profile. 15, 16 The efficacy and safety profile of the SSRI paroxetine has been demonstrated in the treatment of PD in a number of randomized controlled trials. [17] [18] [19] Benzodiazepines are fast acting, effective, well tolerated, and suitable as monotherapy 20, 21 or combination therapy, 22 but they are not considered first-line treatments according to current guidelines because of the risk of adverse events. 15, 16 Benzodiazepines and SSRIs are associated with different adverse event profiles. 10, 12 When patients with PD fail to tolerate the adverse effects associated with a particular drug class, switching to a different drug class can improve the safety outcomes of PD. 10, 23 Drug prescription choice thus depends largely on considerations of adverse event profiles. 10 Besides being effective in the short term, SSRIs, venlafaxine, tricyclic antidepressants, and benzodiazepines are also effective and safe in long-term treatment. 6, 24 Risk of relapse after drug discontinuation is high, and a significant portion of patients experience relapse within 1 year. 6 Discontinuation studies point to a significantly lower risk of relapse in patients on SSRI or serotonin and noradrenaline reuptake inhibitors, compared with patients switched to placebo. 25 Both short-term (6 months) and long-term (12-30 months) treatments were associated with relapse after drug discontinuation. 6, 26 The optimal duration of pharmacotherapy remains unknown, but recent studies recommend at least 12 months of treatment. 27 It is not known at present if 1 pharmacological class or compound is more effective in relapse prevention, because all studies have compared active treatments to placebo.
Relapse was evaluated in a recent study 5 that analyzed data from the US National Epidemiologic Survey on Alcohol and Related Conditions, in which 1939 PD patients completed a 3-year follow-up. Relapse occurred in 13.6% of PD patients, and predictors of relapse were agoraphobia, generalized anxiety disorder, nicotine dependence, female sex, young age, early age at onset of PD, and major financial crisis. 5 Other studies suggest that anxiety sensitivity, 28 residual anxiety symptoms, 29 comorbidity with borderline personality disorder, 30 and psychosocial impairment 31 may also predict relapse in PD. If patients at high risk of relapse could be identified, they would receive longer pharmacological treatments, whereas patients at low risk of relapse would receive shorter treatments. Psychotherapy could also be administered to decrease the risk of relapse in high-risk patients. 6, 32 We hypothesized that patients with more severe PD, more panic attacks, comorbidity with agoraphobia, poor initial response to pharmacological treatment, residual anxiety symptoms after treatment, females, and young patients would relapse more and earlier than others. We expected that pharmacological treatment would not influence relapse rates. The aim of this study was thus to identify factors associated with relapse in PD patients.
MATERIALS AND METHODS

Participants
This ultralong-term follow-up study was conducted subsequent to a short-term, randomized, open clinical trial 33 and a long-term 34-month clinical trial. 24 All patients who concluded the long-term study were invited to enter the current study and were followed up for 6 years. Follow-up was performed at the Institute of Psychiatry of the Federal University of Rio de Janeiro, Brazil.
The clinical trial, comprising both short-and long-term studies, was registered at ClinicalTrials.gov under the identifier NCT02852577.
Inclusion criteria for all 3 studies were as follows: age 18 to 60 years; diagnosis of PD with or without agoraphobia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnostic criteria; and at least 2 panic attacks in the month preceding inclusion in the short-term study. Patients diagnosed as having comorbidities that could affect clinical evaluation, including drug abuse, neurological disorders, or severe personality disorders, were not included.
In order to be included in the current study, patients had to meet the criteria for remission criteria, namely, Clinical Global Impression-Severity (CGI-S) scale 34 score of 1 (normal, not at all ill) and no panic attacks (in the last month) at the end of the long-term study (after 3 years of treatment).
Study Design
This was an observational, prospective, 6-year follow-up study. Patients from previous short-term 33 and long-term studies 24 were invited to participate. The short-term study 33 Those who responded to monotherapy in the short-term study continued with the same drug and dose in the long-term study. 24 Partial responders or nonresponders were invited to receive combined pharmacological treatment with clonazepam and paroxetine. Patients received the maximum tolerated doses of clonazepam and paroxetine. The doses were flexible, ranging from 0.5 to 2 mg/d for clonazepam and from 10 to 40 mg/d of paroxetine. Both drugs were taken at bedtime. Patients were not allowed to receive any form of psychotherapy. The attending psychiatrists did not use CBT techniques or encourage patients to expose themselves to feared situations. All patients received the same instructions about the treatment regardless of the medications they were using.
After 34 months in the long-term study, medications were tapered off during a period of 4 months for clonazepam and 6 weeks for paroxetine. As described previously, 35 in patients on clonazepam monotherapy, the dosage was decreased gradually by 0.5 mg each 2 weeks until reaching 1 mg/d. The dose was then reduced by 0.25 mg per week. If the patient failed to tolerate the tapering because of anxiety or withdrawal symptoms, the process was decelerated by increasing the dose-reduction intervals. In patients on paroxetine, the drug was tapered off by 10 mg per week until reaching 20 mg/d. Further decreases of 5 mg per week were made until total discontinuation was achieved. Drug discontinuation in patients on combination therapy was made simultaneously with both drugs according to the methods described previously. Drug discontinuation was performed in all patients.
Compliance, adherence, and reasons for treatment dropout were discussed in both the short-term 33 and long-term 24 studies. In the ultralong-term study, PD patients were evaluated once a year. Those who relapsed were excluded from the current study and referred to the outpatient clinic of the Institute of Psychiatry of the Federal University of Rio de Janeiro. There they were treated on a naturalistic basis, with medication or psychotherapy.
The study complied with the ethical principles of the Declaration of Helsinki and the Brazilian National Research Ethics Committee guidelines. The local ethics committee approved the study protocol (no. 0003.0.249.000-09). Written informed consent was obtained from all patients.
Assessments
Follow-up assessments were made at 1 (1Y), 2 (2Y), 3 (3Y), 5 (5Y), and 6 (6Y) years after discontinuation of the pharmacological treatment. These included the number of panic attacks per month, CGI-S scores, and the 14-item Hamilton Anxiety Rating Scale (HAM-A) 36 scores (Fig. 1) . Patients who started psychotherapy or pharmacological treatment because of PD symptoms, had CGI-S scores greater than 1, or had panic attacks in the month preceding the assessment were considered relapse cases.
Statistical Analysis
Statistical analysis aimed to identify the variables associated with relapse at 1 year of follow-up year or cumulative relapse rate at 6 years. Predictors of relapse were as follows: age, sex, intensity of PD symptoms (number of panic attacks per month, CGI-S, HAM-A), comorbidity with agoraphobia before treatment (T0), remission after 2 months of treatment (T2), remission after 6 months of treatment (T6), and pharmacological treatment and residual anxiety symptoms (HAM-A score) after 3 years of treatment, at baseline (BL) (Fig. 1) .
Patients with relapse versus without relapse were compared in relation to several variables. Student t test, Mann-Whitney U test, or Pearson χ 2 test was used in these comparisons according to the specific variable. In patients who relapsed, correlations between time in remission and the previously mentioned variables were calculated. Correlation analysis used Spearman rank correlation coefficient for ordinal variables and continuous variables without normal distribution and point biserial correlation coefficient (PBCC) for continuous and dichotomous variables. KaplanMeier survival analysis was performed. Comparisons were also done with log rank, Breslow, and Tarone-Ware. Statistical significance was set at 5%, and all the analyses were two-tailed.
RESULTS
Of the 95 patients that concluded the long-term study, 10 failed to achieve remission. Eighty-five patients achieved remission and were included in the current study. No patients were lost to follow-up, but 19 (22%) had missing data at one or more follow-up assessments, and were not included in all the analyses. The reasons for missing data were that patients could not be reached by telephone or were unwilling to appear at the hospital for the follow-up evaluations.
Patients' mean age was 34 years (SD = 10), 68.2% (n = 58) were female, 55.3% (n = 47) had completed university, 52.9% (n = 45) were married, and 63.5% (n = 54) were working at the time of their acute treatment. At T0, before the short-term treatment, 91.8% (n = 78) presented agoraphobia, the mean number of panic attacks per month was 5 (SD = 3), CGI-S was 4 (SD = 1), HAM-A was 12 (SD = 2), 55.3% (n = 47) of the patients were allocated to receive clonazepam, and the rest received paroxetine. At T2, 62.4% (n = 53) of patients met the criteria for remission, while only 14 (16.5%) had failed to respond favorably to the short-term treatment and underwent augmentation with either clonazepam or paroxetine. At BL, all patients were in remission, and mean HAM-A score was 7 (SD = 3).
Cumulative relapse rates were 50% (n = 33) at 1Y, 63.6% (n = 42) at 2Y, 68.2% (n = 45) at 3Y, 83.5% (n = 71) at 5Y, and 89.4% (n = 76) at 6Y.
With the exception of the psychopharmacological treatment, there were no significant differences between patients who had relapsed versus had not relapsed at 1Y (Table 1 ).
In the comparison of patients with (versus without) history of relapse at 6 years, low HAM-A score at T0 and treatment without clonazepam were associated with high relapse rate ( Table 2) . Patients treated with clonazepam showed consistently lower relapse rates in 6 years compared with patients who had not taken clonazepam (Fig. 2) .
Panic disorder severity, comorbidity with agoraphobia, poor initial response to pharmacological treatment, residual anxiety symptoms after treatment, female sex, and young age were not associated with relapse at 1Y or cumulative relapse at 6Y.
Only treatment with clonazepam (PBCC 0.262; P = 0.015) was associated with time in remission. Treatment with paroxetine (PBCC −0.136; P = 0.214) was not associated with this variable.
In the survival analysis, median survival time was 3 years (95% confidence interval: 2.1-3.9). For patients treated with clonazepam, median survival was 5 years (95% CI: 4.5-5.5), while median survival was 1 year for patients not treated with clonazepam. Comparisons with log rank, Breslow, and Tarone-Ware were all statistically significant and favored the groups treated with clonazepam.
DISCUSSION
Predictors of relapse found in previous studies, such as comorbidity with agoraphobia, 5 residual anxiety symptoms, 29 female sex, 5 and young age 5 did not predict relapse in the present study. In the current study, relapse rates increased over the course of the follow-up years. Treatment with clonazepam predicted low relapse rates in our 6-year posttreatment follow-up.
In Rickels et al, 37 48 PD patients were followed up for 1 year after 8 months of treatment with alprazolam, imipramine, or placebo. Drug discontinuation was achieved in all but 9 patients (19%). Patients who had panic relapse in the follow-up period received naturalistic treatment. Remission rates at 1 year were 85% in patients who completed the 8-month treatment and 55% for those who did not complete the treatment, but there were no significant differences regarding the drug used. 37 A similar study 38 also found that the type of medication did not influence relapse rates.
In the study of Scholten et al, 7 429 anxiety disorder patients in remission were followed for 2 years. Among anxiety disorder patients, 23.5% relapsed, whereas 24.5% of PD patients without comorbidities and 28.0% of patients with PD and agoraphobia FIGURE 1. Timeline. T0 indicates before treatment; Tn, after n months of treatment; BL, baseline of the observational study; TD, treatment discontinuation; nY, number of years from the baseline of the observational study. relapsed during follow-up. Disability, anxiety sensitivity, antidepressant use, residual anxiety, and avoidance symptoms predicted relapse, but disability and anxiety sensitivity were the only independent predictors of relapse in the multivariate model. Age, sex, and psychological treatment did not correlate with relapse rates. 7 Taylor et al 39 followed 274 remitted anxiety disorder patients for 12 months and found relapse rates of 33% for any anxiety disorder and 36% for PD. For PD patients treated with the "collaborative care" strategy, the relapse rate was significantly lower (32% vs 45%) compared with those treated with the "usual care" strategy before follow-up. In the multivariate logistic regression model, the authors identified smoking, single marital status, treatment with benzodiazepines, anxiety sensitivity, and functional impairment (due to residual anxiety) as strong predictors of recurrence. 39 In the study of Heldt et al, 29 PD patients who achieved remission after group CBT and pharmacological treatment were followed up for 2 years. The relapse rate was 30% (n = 17). Among several independent variables, only stressful life events ("conflict") and residual anxiety symptoms predicted relapse. Among patients with recurrence, 71% (n = 12) were on antidepressants, and 24% (n = 4) were on benzodiazepines, but this difference did not reach statistical significance. 29 The results of the previously mentioned studies 7, 29, [37] [38] [39] should be interpreted with caution, because patients were allowed to receive pharmacological treatment or CBT in the follow-up phase of these studies. If several studies 6, 25, 26 indicate that treatment discontinuation predicts relapse and maintenance treatment protects against relapse, continuous pharmacological treatment or CBT in a subgroup of PD patients could produce biased results. Besides, patients prone to chronicity are more likely to be kept on medications or CBT for long periods, thus artificially diminishing the relapse rates.
In the current study, treatment was discontinued in all patients in remission, who did not receive any kind of treatment in the follow-up unless they experienced a relapse. In discontinuation studies with imipramine, 26, [40] [41] [42] relapse rates at 1 year ranged from 29% to 37%, whereas in the current study these rates were 34% for clonazepam and 62% for paroxetine. Selective serotonin reuptake inhibitors, tricyclic antidepressants, and benzodiazepines have several pharmacological differences that could explain different posttreatment relapse rates. Meanwhile, we could speculate that the tapering of clonazepam (4 months) was adequate, but that the tapering of paroxetine was too fast (6 weeks), thus promoting relapse. Besides, the choice of medication was randomized, and there were no differences between the clonazepam and paroxetine groups at BL. 33 Several studies have indicated that both antidepressants 43, 44 and benzodiazepines 45 produce neurobiological changes in longterm use, but it is still not clear if these changes persist after suspending administration of these drugs. It has been hypothesized 46 that benzodiazepine tolerance after chronic administration may be due to a shift to a perisynaptic or extrasynaptic localization of γ-aminobutyric acid A (GABA A ) receptors, away from clustering of GABA A receptors at synapses. This would produce a loss in synaptic function of benzodiazepines and consequent tolerance. 46 Nevertheless, the increased density of extrasynaptic GABA A receptors, which usually contain a σ subunit and are much more sensitive to GABA and have slow desensitization kinetics, 47 could contribute to extrasynaptic tonic inhibition, which has been suggested as modulating neuronal network excitability throughout the brain. The extrasynaptic GABA A receptor α 4 β n σ/γ is distributed in the hippocampus, thalamus, and cortex 45 and may have a role in the pathophysiology of anxiety disorders. Long-term administration of benzodiazepines and consequent enhancement of the GABA system may evoke changes in the synthesis and metabolism of neurosteroids, which, in turn, have plasticity-inducing actions on inhibitory signaling. 48 There is abundant evidence in the literature that neurosteroids are endogenous allosteric regulators that interact with GABA A receptors to modulate both tonic (extrasynaptic) and phasic (synaptic) inhibition. 45, 49, 50 In addition, acute or chronic neurosteroid treatment may change GABA A receptor subunit expression, especially extrasynaptic α 4 and σ subunits. 50 Assuming that benzodiazepines produce enduring neurobiological changes, even after the cessation of drug administration, these changes could prevent anxiety recurrence.
In the current study, age at onset of PD, anxiety sensitivity, stressful live events, psychosocial impairment, comorbidities with generalized anxiety disorder, borderline personality disorder, and nicotine dependence, which are potentially associated with relapse, were not evaluated. Because of small sample size and low statistical power, predictors of relapse with small effect sizes could not be identified. Patients and investigators knew what kind of treatment each patient received, because treatment was not blinded. Although unlikely, it is impossible to completely rule out the fact that knowing the treatment could influence the outcome and measures in this study.
Two limitations of this study could lead to underestimation of relapse cases and inflation of the estimated time in remission. The lack of an evaluation after 4 years of follow-up and missing data for 19 patients could produce false relapse dates, later than the real relapse dates, thereby increasing the mean time in remission. Because of the methods used to detect relapse in the current study, patients who experienced panic attacks and other PD symptoms but improved spontaneously at least 1 month before the subsequent evaluation would not be considered relapse cases. If some relapse cases were not detected, the real incidence of relapse is even higher than the one reported in the current study. Nevertheless, the proportion of undetected relapse cases among patients previously treated with clonazepam or paroxetine should be about the same.
It was demonstrated that recurrence is a common problem in PD, and long-term treatment does not protect these patients in the long run. Treatment with clonazepam appears to protect these patients against relapse, but further studies are needed to support this affirmation.
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